Global InformationPirtobrutinib information
 | |
| Clinical data | |
|---|---|
| Trade names | Jaypirca |
| Other names | LOXO-305 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a623012 |
| License data |
|
| Routes of administration | By mouth |
| Drug class | Protein kinase inhibitor |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number |
|
| PubChem CID |
|
| DrugBank |
|
| ChemSpider |
|
| UNII |
|
| KEGG |
|
| ChEBI |
|
| ChEMBL |
|
| PDB ligand |
|
| Chemical and physical data | |
| Formula | C22H21F4N5O3 |
| Molar mass | 479.436 g·mol−1 |
| 3D model (JSmol) |
|
SMILES
| |
InChI
| |
Pirtobrutinib, sold under the brand name Jaypirca, is an anticancer medication that is used to treat mantle cell lymphoma.[1][2][4] It inhibits B cell lymphocyte proliferation and survival by binding and inhibiting Bruton's tyrosine kinase (BTK).[5] It is taken by mouth.[1]
The most common adverse reactions include fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.[4][6] The most common adverse reactions when used to treat chronic lymphocytic leukemia or small lymphocytic leukemia include fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache.[7]
Pirtobrutinib was approved for medical use in the United States in January 2023,[4][8][9][10] and in the European Union in November 2023.[2]
- ^ a b c Cite error: The named reference
Jaypirca FDA labelwas invoked but never defined (see the help page). - ^ a b c "Jaypirca EPAR". European Medicines Agency (EMA). 20 November 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023.
- ^ "Jaypirca Product information". Union Register of medicinal products. 31 October 2023. Archived from the original on 22 November 2023. Retrieved 22 November 2023.
- ^ a b c "FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma". FDA. 27 January 2023. Archived from the original on 28 January 2023. Retrieved 28 January 2023.
This article incorporates text from this source, which is in the public domain.
- ^ Aslan B, Kismali G, Iles LR, Manyam GC, Ayres ML, Chen LS, et al. (May 2022). "Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia". Blood Cancer Journal. 12 (5): 80. doi:10.1038/s41408-022-00675-9. PMC 9123190. PMID 35595730.
- ^ Cite error: The named reference
FDA snapshotwas invoked but never defined (see the help page). - ^ Cite error: The named reference
FDA 20231201was invoked but never defined (see the help page). - ^ "U.S. FDA Approves Jaypirca (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor" (Press release). Eli Lilly. 27 January 2023. Archived from the original on 30 January 2023. Retrieved 31 January 2023 – via PR Newswire.
- ^ Keam SJ (April 2023). "Pirtobrutinib: First Approval". Drugs. 83 (6): 547–553. doi:10.1007/s40265-023-01860-1. PMID 37004673. S2CID 257912433. Archived from the original on 19 November 2023. Retrieved 19 November 2023.
- ^ Telaraja D, Kasamon YL, Collazo JS, Leong R, Wang K, Li P, et al. (August 2023). "FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma". Clinical Cancer Research. 30 (1): OF1–OF6. doi:10.1158/1078-0432.CCR-23-1272. PMC 10841293. PMID 37624619. S2CID 265965744.
